【会長講演】 【特別講演】 - congre.co.jp

1 277 .. 10 13 15 00 16 00 1 1F . : .. 1 . 10 12 8 50 9 40 1 1F . : . Reimagining dementia : neuroreflections on past, present, and future Peter J. Whitehouse Transdisciplinary Professor, Case Western Reserve University and University of Toronto 2 . 10 13 9 10 10 00 1 1F . : . Understanding Alzheimer's as a Disease of Chronic Oxidative Stress George Perry Dean and Professor, Semmes Foundation Distinguished University Chair in Neurobiology College of Sciences, The University of Texas at San Antonio, San Antonio, TX.. 1. 10 12 8 50 9 40 2 3F A . : .. 23 . 278 Dementia Japan Vol. 32 No. 3 September 2018. 2. 10 12 8 50 9 40 3 3F BC . : .. 3. 10 12 8 50 9 40 4 2F . : .. 4. 10 12 8 50 9 40 5 2F . : . BPSD .. 5. 10 12 8 50 9 40 6 2F . : .. 6. 10 13 9 10 10 00 2 3F A.

2 24 . 279 . 7. 10 13 9 10 10 00 3 3F BC . : .. 8. 10 13 9 10 10 00 4 2F . : . ; Update .. 9. 10 13 9 10 10 00 5 2F . : .. MRI .. 10. 10 13 9 10 10 00 6 2F . : .. 11. 10 14 9 00 9 50 2 3F A . : . Recent progress in microglia and exosome pathway as novel therapeutic targets of Alzheimer's disease Tsuneya Ikezu Boston University School of Medicine, Boston, Massachusetts, United States 25 . 280 Dementia Japan Vol. 32 No. 3 September 2018. 12. 10 14 9 00 9 50 3 3F BC . : .. 13. 10 14 9 00 9 50 4 2F . : .. 14. 10 14 9 00 9 50 5 2F . : .. 15. 10 14 9 00 9 50 6 2F . : . PSP CBD : an update .. 1. 10 12 9 00 9 50 7 1F . : . : .. 26 . 281 . 2. 10 12 10 00 10 50 7 1F . : .. 3. 10 12 11 00 11 50 7 1F . : . : .. 4. 10 12 13 30 14 20 7 1F . : .. 5. 10 12 14 30 15 20 7 1F.

3 6. 10 12 15 30 16 20 7 1F . : .. 27 . 282 Dementia Japan Vol. 32 No. 3 September 2018. 7. 10 13 9 10 10 00 7 1F . : .. 8. 10 13 10 20 11 10 7 1F . : . PET .. 9. 10 13 11 20 12 10 7 1F . : .. 10. 10 13 16 20 17 10 7 1F . : .. 11. 10 13 17 20 18 10 7 1F . : .. 28 . 283 . 12. 10 14 9 00 9 50 7 1F . : .. 13. 10 14 10 00 10 50 7 1F . : .. 14. 10 14 11 10 12 00 7 1F . : .. 1 . 10 12 10 00 12 00 1 1F . : .. 1.. 2.. 3.. 4.. 29 . 284 Dementia Japan Vol. 32 No. 3 September 2018. 2 . 10 12 10 00 12 00 2 3F A . : iPS / .. 1. ; .. 2. in vitro trial . iPS . 3.. 4. microRNA .. 3 EBM. 10 12 10 00 12 00 3 3F BC . : .. 1.. 2. BPSD .. 3.. 4.. 4 . 10 12 10 00 12 00 4 2F . : .. 1. A .. 2. A p3-Alc .. 30 . 285 . 3.. 4. A KLK7 .. 5. A .. 5 BPSD . 10 12 10 00 12 00 5 2F . : .. 1.. 2. BPSD.

4 3. BPSD .. 4. BPSD AI Nursing .. 6 20 . 10 12 10 00 12 00 6 2F . : .. 1. 20 .. 2.. 3.. 4.. 31 . 286 Dementia Japan Vol. 32 No. 3 September 2018. 7 . 10 12 13 30 15 30 1 1F . : .. 1.. 2.. 3.. 4.. 8 glymphatic . 10 12 13 30 15 30 2 3F A . : .. 1. Glymphatic system MRI.. 2. 4 .. 3.. 4.. 9 . 10 12 13 30 15 30 3 3F BC . : .. 1. : .. 2. Risk and protective factors for dementia in a community : the Hisayama Study . 32 . 287 . 3.. 4.. 10 .. 10 12 13 30 16 00 4 2F . : .. 1. Factors Important to the Development of New Alzheimer's Disease Therapies Biogen Inc. Samantha Budd Haeberlein 2. First step toward disease modification in AD-targeting beta amyloid and tau proteinopathies Global Head of Neurodegeneration and AD Franchise Head PD Neuroscience F. Hoffmann-La Roche Ltd.

5 Rachelle S. Doody 3. BACE1 Inhibitor CNP520 in the Alzheimer Prevention Initiative API Generation Program Global Program Head, Neuroscience, Novartis Pharma AG Ana Graf 4. The role of amyloid and tau PET imaging in therapeutic clinical trials for Alzheimer's Disease Vice President of Imaging, Avid Radiopharmaceuticals a wholly owned subsidiary of Eli Lilly . Michael D. Devous 5. Clinical Development for Early Alzheimer's Disease Based on the Amyloid Hypothesis Neurology Business Group, Eisai Inc., Wood Cliff Lake, NJ, USA Johan Luthman 6. Clinical Studies in Asymptomatic Subjects at High Risk for Alzheimer's Disease AD . Janssen Research and Development, Fremont, California, USA John Thipphawong 11 . 10 12 13 30 15 30 5 2F . : / .. 1.. / . 2.. TMG . 3.. 33 . 288 Dementia Japan Vol.

6 32 No. 3 September 2018. 4.. 12 . 10 12 13 30 15 30 6 2F . : .. 1.. 2.. 3.. 4.. 13 . 10 13 10 20 12 20 1 1F . : .. 1.. 2. A .. 3.. 4. APOE and TREM2 as key microglial molecules for neurodegenerative phenotypes in Alzheimer's disease Boston University School of Medicine, Boston, Massachusetts, United States Tsuneya Ikezu 14 . 10 13 10 20 12 20 2 3F A . : .. 1.. 34 . 289 . 2.. 3.. D . 4.. NPO . 15 : ICT . 10 13 10 20 12 20 3 3F BC . : . NTT . 1. ICT . NTT . 2.. 3. Cognitive Assessment for Dementia, iPad version 2 CADi2 .. 4.. 16 . 10 13 10 20 12 20 4 2F . : .. 1. : .. 2.. 3.. 4.. 35 . 290 Dementia Japan Vol. 32 No. 3 September 2018. 17 : . 10 13 10 20 12 20 5 2F . : .. 1.. 2. : .. 3. : .. 4.. 18 . 10 13 10 20 12 20 6 2F . : .. 1.. 2. Cnm Streptococcus mutans . 3.

7 4.. 19 progress pitfall 10 13 16 20 18 20 2 3F A . : .. 1. progress pitfall : MRI.. 2. SPECT .. 36 . 291 . 3. MIBG .. 4. DAT .. 20 . 10 13 16 20 18 20 3 3F BC . : .. 1. : .. 2.. 3.. 4.. 21 . 10 13 16 20 18 20 4 2F . : .. 1.. WPI-IIIS .. 2.. 3.. 4.. 37 . 292 Dementia Japan Vol. 32 No. 3 September 2018. 22 . 10 14 10 00 12 00 2 3F A . : .. 1.. 2.. 3.. 4.. 23 .. 10 14 10 00 12 00 3 3F BC . : .. 1.. 2.. 3.. 4.. 24 . 10 14 . 10 00 12 00 4 2F . : .. 1. DNA .. 2. TDP-43 .. 38 . 293 . 3. RNA .. 4. RNA RAN .. 25 . 10 14 10 00 12 00 6 2F . : .. 1.. 2.. 3.. 4.. 26 Suspected non-Alzheimer disease pathophysiology SNAP . 10 14 13 30 15 30 2 3F A . : .. 1. Primary age-related tauopathy PART .. 2. Argyrophilic grain disease . 3. Cerebral age-related TDP-43 pathology and arteriolosclerosis CARTS.

8 4. SNAP PET .. 39 . 294 Dementia Japan Vol. 32 No. 3 September 2018. 27 . 10 14 13 30 15 30 3 3F BC . : .. 1. DLB .. 2. DLB .. 3. DLB pitfall . 4. DLB .. 28 . 10 14 13 30 15 30 4 2F . : .. 1.. 2.. 3. mRNA .. 4.. 29 . 10 14 13 30 15 30 5 2F . : .. 1.. 2.. 40 . 295 . 3.. 4.. 30 . 10 14 13 30 15 30 6 2F . : .. 1. treatable dementia : .. 2.. 3.. 10 14 10 00 12 00 5 2F . : .. 1. REST : .. 2.. 3.. 4. KEAP1-NRF2 .. 41 . 296 Dementia Japan Vol. 32 No. 3 September 2018.. 10 13 16 20 17 20 1 1F . : . 1. TDP-43 .. 2. A 42 43 .. 37 .. 10 14 13 : 20 15 : 20 1F . : . : .. 1 ABC . 10 12 12 20 13 10 1 1F . : . : . : . AD ADL BPSD Cognitive function . AD . ABC AD .. 42 . 297 . 2 . 10 12 12 20 13 10 2 3F A . : . : . : .. PMDA . GLP, non-GLP . GMP . STR01 2016 2 .. STR01 . 3 . 10 12 12 20 13 10 3 3F BC.

9 : / . : . : . 1 kg . 1 .. neurovascular unit, NVU NVU . small vessel disease .. 4 Unmet Need in Neuroscience 10 12 12 20 13 10 4 2F . Sponsor : Chugai Pharmaceutical Co., Ltd. : Hiroyuki Arai Institute of Development, Aging and Cancer, Tohoku University . : Rachelle Doody Global Head of Neurodegeneration, Roche Ltd.. One of the greatest areas of unmet need remaining in medicine is the need for disease modifying drugs for congenital and chronic neurological diseases. At Roche, we are targeting Multiple Sclerosis ; Neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, Huntington's disease, and Amyotrophic Lateral Sclerosis ;. Neuromuscular diseases, especially Spinal Muscular Atrophy ; and the Neurodevelopmental disorder, Autism. Our approach to each disease is driven by the extent of our scientific understanding of these diseases, and our belief that the intervention is potentially transformational.

10 In MS, we believe that treatments targeting B Cells are able to affect all forms of the disease, both relapsing remitting and chronic progressive. For Alzheimer's and Parkinson's disease, we target the proteinopathies of these diseases with monoclonal antibodies. For the rapidly progressive disorder, ALS, we target the pathway involved with cell death. For the genetic disorders of SMA and HD, we utilize gene modifying therapies, and our approach to Autism is based upon the neuroendocrine targets known to be associated with social behaviour. The ultimate goal is to provide lasting and impactful therapies for these disorders. 43 . 298 Dementia Japan Vol. 32 No. 3 September 2018. 5 . 10 12 12 20 13 10 5 2F . : . : . 1.. : . 2.. : / .. TEA .. 6 : . 10 12 12 20 13 10 6 2F.